Pfizer : PFE

All Pfizer Articles

1465 Articles

Vince Calio | May 8, 2014 at 10:53 AM EDT

The Best-Selling Products of All Time

ThinkstockCreating the most popular product of the year will make consumers and investors happy. But making an all-time bestseller can…

Paul Ausick | May 6, 2014 at 4:01 PM EDT

The 4 Stocks That Tanked the Market

thinkstockMay 6, 2014: Markets opened lower on Monday and sank slowly and surely for the rest of the day. The…

Paul Ausick | May 6, 2014 at 11:05 AM EDT

Cross-Border Premium Implications in Merck-Bayer Transaction

Merck has had its consumer products business on the market since the beginning of this year, and Tuesday it announced…

Paul Ausick | May 5, 2014 at 4:01 PM EDT

The 4 Stocks That Moved the Markets

thinkstockMay 5, 2014: Markets opened lower on Monday but gamely pushed to the upside in midafternoon. General concern over the…

Paul Ausick | May 5, 2014 at 8:00 AM EDT

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

Drug giant Pfizer reported better-than-expected first-quarter 2014 earnings before markets opened Monday morning, but revenues fell short. Shares traded lower…

Jon C. Ogg | May 4, 2014 at 10:32 AM EDT

The Top Eight Earnings for the Week Ahead

Jon OggEarnings season is far from over, but roughly three quarters of the stocks in the Standard & Poor’s 500 Index…

Paul Ausick | May 2, 2014 at 8:55 AM EDT

AstraZeneca Declares Pfizer Bid ‘Inadequate’

British drug maker AstraZeneca once again rejected a takeover bid from U.S. pharmaceutical giant Pfizer, this one worth $106 billion…

Paul Ausick | Apr 28, 2014 at 4:01 PM EDT

The 4 Stocks That Led Markets Higher

thinkstockApril 28, 2014: Markets opened higher on Monday with little economic data to drive the market either up or down.…

cgblaine22 | Apr 26, 2014 at 8:30 AM EDT

Biotech: The Poster Child for Market Volatility in 2014

The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5.…

Jon C. Ogg | Apr 23, 2014 at 8:50 AM EDT

UBS Top Stocks to Buy Working for Cancer Cures

In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are…

Paul Ausick | Apr 21, 2014 at 4:40 PM EDT

The 4 Stocks That Boosted Markets

thinkstockApril 21 2014: Markets opened higher on Monday but there wasn’t a lot of action as the only data out…

Jon C. Ogg | Apr 21, 2014 at 1:25 PM EDT

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

ThinkstockIt is not that common that you hear about mergers in the $50 billion range. But what about when you…

Jon C. Ogg | Apr 16, 2014 at 10:40 AM EDT

Why Lpath Could Rise 300%

Canaccord Genuity is one of the few firms that are willing to cover small-cap biotech and emerging pharma stocks. Sometimes…

Paul Ausick | Apr 7, 2014 at 4:27 PM EDT

The 4 Stocks That Slammed the Market

thinkstockApril 7, 2014: Markets opened lower on Monday and were on a downhill slide all day long. Momentum stocks again…

Jon C. Ogg | Apr 7, 2014 at 11:00 AM EDT

FDA Keeps Driving Up Future Cost of Inhalable Insulin

While the FDA has been far from a friend to MannKind over the past few years, the latest FDA panel…

1 … 64 65 66 67 68 … 98

Pfizer : PFE

All Pfizer Articles

The Best-Selling Products of All Time

The 4 Stocks That Tanked the Market

Cross-Border Premium Implications in Merck-Bayer Transaction

The 4 Stocks That Moved the Markets

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

The Top Eight Earnings for the Week Ahead

AstraZeneca Declares Pfizer Bid ‘Inadequate’

The 4 Stocks That Led Markets Higher

Biotech: The Poster Child for Market Volatility in 2014

UBS Top Stocks to Buy Working for Cancer Cures

The 4 Stocks That Boosted Markets

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

Why Lpath Could Rise 300%

The 4 Stocks That Slammed the Market

FDA Keeps Driving Up Future Cost of Inhalable Insulin

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

Rivian Tops Q1 Estimates, but Investors Investors Rightly Remain Wary

Ray Dalio Warns U.S. Faces ‘Particularly Risky Period’ Between 2026 and 2028 Elections

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

A Couple With $3.5 Million Discovers State Estate Taxes Could Cost Their Kids Six Figures

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

Rivian Tops Q1 Estimates, but Investors Investors Rightly Remain Wary

Pfizer : PFE

All Pfizer Articles

The Best-Selling Products of All Time

The 4 Stocks That Tanked the Market

Cross-Border Premium Implications in Merck-Bayer Transaction

The 4 Stocks That Moved the Markets

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

The Top Eight Earnings for the Week Ahead

AstraZeneca Declares Pfizer Bid ‘Inadequate’

The 4 Stocks That Led Markets Higher

Biotech: The Poster Child for Market Volatility in 2014

UBS Top Stocks to Buy Working for Cancer Cures

The 4 Stocks That Boosted Markets

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

Why Lpath Could Rise 300%

The 4 Stocks That Slammed the Market

FDA Keeps Driving Up Future Cost of Inhalable Insulin

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

Rivian Tops Q1 Estimates, but Investors Investors Rightly Remain Wary

Ray Dalio Warns U.S. Faces ‘Particularly Risky Period’ Between 2026 and 2028 Elections

Featured Reads

Why 56% of Americans Are Losing the Inflation Fight Before Retirement Even Starts

A Couple With $3.5 Million Discovers State Estate Taxes Could Cost Their Kids Six Figures